Panbela Therapeutics, Inc.
PBLA · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | -0.05 | 0.13 |
| FCF Yield | -1,269,402.96% | -1,061.02% | -33.10% | -14.00% |
| EV / EBITDA | -0.05 | -0.20 | -0.79 | -3.67 |
| Quality | ||||
| ROIC | -10,520.48% | 2,819.93% | -93.52% | -64.14% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.00 | 0.44 | 0.66 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -58.44% | -137.71% | -73.95% | -40.71% |
| Safety | ||||
| Net Debt / EBITDA | -0.05 | -0.16 | 1.12 | 1.79 |
| Interest Coverage | 161.81 | -118.38 | -910.00 | -338.47 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -141.45 | -29.27 | -23.34 | -35.14 |